Chemistry data
- Class
- glycoprotein / myostatin-binding protein
- Molecular weight
- 38007 g/mol
- Half-life
- hours (serum FS315 circulating form); sustained expression when delivered via AAV gene therapy
- Routes
- intramuscular (gene therapy, AAV1 vector) · intravenous (recombinant protein, investigational)
- Studied doses
- intramuscular (AAV1 gene therapy) 3×10¹¹ to 1.2×10¹² vg/kg (vector genomes per kg body weight) · intramuscular (AAV1 gene therapy) 1×10¹⁰ to 1×10¹¹ viral particles per animal
Most peptides in muscle research work by adding something — a growth signal, a recovery factor, a hormonal trigger. Follistatin-344 works by removing a brake.
The human body produces a protein called myostatin (GDF-8) whose primary function is to limit muscle growth. It is an evolutionary safeguard against excessive muscle mass — a built-in governor on the engine of hypertrophy. Follistatin-344 is a naturally occurring glycoprotein that binds myostatin directly, preventing it from activating the SMAD signaling cascade that tells muscle cells to stop growing PMID: 20810712 .
The result, demonstrated across preclinical models and early-phase human trials, is substantial muscle hypertrophy — not by introducing foreign growth signals, but by neutralizing the body's own growth-limiting mechanism. In follistatin-overexpressing mice, researchers documented muscle mass increases of 194–327%, exceeding even myostatin knockout models PMID: 18334646 .
This distinction matters. Follistatin does not merely block one pathway; it engages multiple TGF-β superfamily ligands, including activin A and GDF-11, while simultaneously activating the Akt/mTOR anabolic axis through mechanisms that operate independently of myostatin PMID: 22711699 . The result is a compound with a unique dual mechanism — removing a catabolic signal while amplifying anabolic ones.
Regulatory Status
- United States
- Investigational Gene Therapy
- European Union
- Research use only
- United Kingdom
- Research use only
What is this compound?
Follistatin-344 is one of two protein isoforms produced by alternative splicing of the human FST gene. The gene encodes a 344-amino-acid precursor protein (FS344) that, after cleavage of its 29-amino-acid signal peptide, circulates as FS315 — the serum-active form. A second isoform, FS317 (circulating as FS288), is also produced but exhibits significantly higher affinity for activin, which carries implications for reproductive hormone regulation PMID: 25322757 .
The FS344/FS315 isoform was deliberately selected for therapeutic development because of its approximately 10-fold lower activin affinity compared to FS288. This selectivity matters: activin plays roles in follicle-stimulating hormone (FSH) regulation, and a therapeutic agent that broadly suppressed activin could disrupt reproductive endocrinology. FS315 retains potent myostatin binding while minimizing off-target endocrine effects PMID: 18334646 .
Structurally, follistatin contains an N-terminal domain and three follistatin domains (FS domains) that mediate ligand binding. The protein's interaction with myostatin is not a simple one-to-one binding event — follistatin forms a ternary complex with myostatin and the co-receptor cripto, physically preventing myostatin from engaging the activin type II receptor (ActRIIB) that would otherwise initiate SMAD signaling PMID: 20810712 .
Follistatin-344 is not a small synthetic peptide. At approximately 38 kilodaltons, it is orders of magnitude larger than compounds like BPC-157 
BPC-157 pentadecapeptide Gastrointestinal protection & systemic tissue repair (1.4 kDa) or ipamorelin 
Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue (0.7 kDa). This size precludes conventional subcutaneous peptide administration. Therapeutic delivery has relied on AAV1 (adeno-associated virus serotype 1) gene therapy — a single intramuscular injection that instructs muscle cells to produce follistatin endogenously, bypassing the need for repeated protein administration.
How it works
Follistatin-344 operates through a mechanism fundamentally different from most peptides in the muscle research space. Rather than activating a growth pathway directly, it neutralizes the primary molecular brake on muscle growth — myostatin — while simultaneously engaging additional anabolic signaling through SMAD-independent routes PMID: 22711699 .
The first and most characterized mechanism is myostatin sequestration. Myostatin, a member of the TGF-β superfamily, signals by binding to the activin type II receptor (ActRIIB) on muscle cell surfaces. This binding triggers phosphorylation of SMAD2 and SMAD3 intracellular transcription factors, which translocate to the nucleus and activate gene programs that suppress muscle protein synthesis and promote muscle protein breakdown. Follistatin binds myostatin with high affinity before it can reach ActRIIB, forming an inactive complex that is cleared from circulation [PMID: 20810712, 19208403].
The second mechanism involves activin A neutralization. Activin A signals through the same ActRIIB-SMAD2/3 axis as myostatin and independently suppresses muscle growth. By binding activin A, follistatin removes a second SMAD-dependent growth inhibitor — one that myostatin-only interventions would leave unchecked PMID: 20810712 .
Third, follistatin engages the Akt/mTOR/S6K/S6RP signaling axis through a pathway that operates independently of myostatin blockade. Research by Winbanks et al. (2012) demonstrated that follistatin-mediated muscle hypertrophy requires Smad3, but also activates Akt phosphorylation and downstream mTOR signaling — the same master growth pathway targeted by anabolic compounds. Critically, this Akt activation was shown to be independent of myostatin inhibition, explaining why follistatin overexpression produces greater hypertrophy than myostatin knockout alone PMID: 22711699 .
The combined effect — SMAD pathway blockade plus Akt/mTOR activation — creates a dual mechanism: catabolic signals are suppressed while anabolic signals are amplified. This distinguishes follistatin from agents that only block myostatin (such as anti-myostatin antibodies) or only activate growth pathways (such as IGF-1 analogues).
- Myostatin (GDF-8) binding and neutralization via ActRIIB receptor blockade
- SMAD2/SMAD3 signaling inhibition — blocks myostatin/activin intracellular signal transduction
- Activin A and GDF-11 neutralization (TGF-β superfamily ligand binding)
- Akt/mTOR/S6K pathway activation — muscle hypertrophy signaling independent of myostatin blockade
Research Findings
The most robust evidence for follistatin-344 comes from preclinical models of muscular dystrophy and from early-phase human gene therapy trials. These findings span muscle mass, functional strength, pathological markers, and long-term durability.
Muscle hypertrophy represents the most dramatic preclinical finding. Mice engineered to overexpress follistatin exhibited muscle mass increases of 194–327% — substantially exceeding the ~200% increase observed in myostatin knockout mice PMID: 18334646 . This gap confirms that follistatin's mechanism extends beyond myostatin blockade alone. The hypertrophy involved both hyperplasia (increased fiber number) and hypertrophy (increased fiber diameter), a combination rarely observed with single-pathway interventions.
In the mdx mouse model of Duchenne muscular dystrophy, AAV1-FS344 gene therapy improved muscle mass and strength while reducing hallmarks of dystrophic pathology: necrosis, inflammation, and endomysial fibrosis. Importantly, these benefits persisted for over 560 days following a single injection, and were effective even when treatment began in aged animals (210 days) with established pathology PMID: 18334646 .
Human clinical data, though limited to small Phase I/IIa trials, provides proof-of-concept. In six ambulatory Becker muscular dystrophy patients receiving AAV1-FS344 intramuscular injections, researchers observed a statistically significant 11.5% improvement in the 6-Minute Walk Test at 6 months (p=0.02). Four of six patients showed meaningful ambulation improvement, with gains up to 108 meters. The two non-responders had extensive baseline muscle fibrosis, suggesting that earlier intervention may be critical PMID: 25322757 .
Reproductive safety — a key concern given follistatin's activin-binding capacity — was assessed in both preclinical and clinical settings. Treated mice showed normal litter sizes compared to controls. In the Becker MD trial, no disruption of reproductive hormones was observed. The selection of the FS344 isoform (lower activin affinity than FS288) was specifically designed to minimize this risk [PMID: 18334646, 25322757].
A 2020 study by Tang et al. demonstrated that follistatin gene therapy also prevented obesity and metabolic disease in mouse models, and attenuated post-traumatic osteoarthritis — suggesting benefits extending beyond muscle tissue into systemic metabolic health PMID: 32320040 .
- muscle-hypertrophy preclinical_and_clinical
- muscular-dystrophy-therapy clinical_phase_1_2a
- muscle-strength-enhancement preclinical
- reduced-muscle-fibrosis preclinical
- metabolic-health preclinical
Dosage Context Explained
Follistatin-344 dosing in research differs fundamentally from conventional peptide administration. Because the protein is too large for practical repeated injection, therapeutic approaches have relied on AAV1-mediated gene therapy — a single intramuscular injection that enables sustained, endogenous follistatin production by transduced muscle cells.
The Phase I/IIa clinical trial in Becker muscular dystrophy employed a dose-ascending design across two cohorts. The low-dose cohort received 3×10¹¹ vector genomes (vg) per kilogram per leg (total 6×10¹¹ vg/kg), while the high-dose cohort received 6×10¹¹ vg/kg per leg (total 1.2×10¹² vg/kg). Injections were administered under ultrasound guidance into three of four quadriceps muscles. Patients received prednisone immunosuppression beginning one month before injection to mitigate immune responses to the AAV1 capsid PMID: 25322757 .
Preclinical mouse studies utilized viral particle doses of 1×10¹⁰ to 1×10¹¹ per animal, delivered via bilateral intramuscular injection into the quadriceps and tibialis anterior. The higher dose produced serum follistatin levels of approximately 15.3 ng/mL, compared to 6.8 ng/mL at the lower dose PMID: 18334646 .
It is essential to note that no standardized dosing for recombinant follistatin protein administration exists. The gene therapy approach circumvents the pharmacokinetic challenges of repeated large-protein injection by converting the patient's own muscle tissue into a sustained follistatin production facility. Any non-gene-therapy dosing would be strictly investigational and without established human protocols.
Direct translation from animal vector doses to human dosing is not straightforward. Species differences in muscle mass, AAV tropism, immune response to viral vectors, and follistatin clearance rates complicate extrapolation. The clinical trial doses were selected based on preclinical efficacy data and escalating safety assessments, not simple allometric scaling.
-
- Administration Routes
- intramuscular (AAV1 gene therapy)
- Range
- 3×10¹¹ to 1.2×10¹² vg/kg (vector genomes per kg body weight)
Phase I/IIa clinical trial in Becker muscular dystrophy (Mendell et al. 2015)
-
- Administration Routes
- intramuscular (AAV1 gene therapy)
- Range
- 1×10¹⁰ to 1×10¹¹ viral particles per animal
Preclinical mouse models (Rodino-Klapac et al. 2008)
🧮 Reconstitution Calculator
Determine exactly how much bacteriostatic water to add and how many units to draw for your target dose.
Side Effects: Research Context
The safety profile of follistatin-344 gene therapy has been evaluated in preclinical studies and one Phase I/IIa human trial, with follow-up periods extending to 12 months. While the data is limited in scale, the findings are notable for the absence of serious treatment-related adverse events.
In the Becker muscular dystrophy trial (n=6), no significant adverse events attributable to gene transfer were reported during the follow-up period. The most common intervention-related effects were managed through the prednisone immunosuppression protocol — standard for AAV gene therapy — which itself carries transient side effects including mood changes, appetite increase, and immune suppression during the dosing window PMID: 25322757 .
Preclinical safety studies in non-human primates (cynomolgus macaques) demonstrated follistatin expression lasting beyond 15 months with no evidence of organ toxicity, cardiac pathology, or reproductive impairment. Mice treated with AAV1-FS344 showed normal cardiac histology and maintained normal reproductive function, with litter sizes indistinguishable from untreated controls PMID: 18334646 .
The theoretical safety concern most frequently raised is the potential for myostatin inhibition to promote malignancy in individuals with undetected tumors, given that growth signaling pathways are shared between muscle hypertrophy and tumor growth. This concern, while mechanistically plausible, has not been supported by any adverse signal in preclinical or clinical data. However, the limited sample sizes and follow-up durations mean this remains an unresolved question requiring larger, longer trials.
A practical limitation of AAV1-based delivery is pre-existing immunity to AAV capsids in some individuals. Prior exposure to wild-type AAV can generate neutralizing antibodies that reduce gene transfer efficiency, potentially rendering the therapy less effective. This is a limitation of the delivery vector, not of follistatin itself.
- injection site reactions (clinical trials)
- potential immune response to AAV vector (managed with corticosteroid immunosuppression)
- no reported adverse effects on cardiac tissue or reproductive capacity in preclinical or clinical studies
Frequently Asked Questions
Frequently Asked Questions
-
Follistatin-344 is a naturally occurring human glycoprotein — a 344-amino-acid protein encoded by the FST gene — that binds and neutralizes myostatin, activin A, and other TGF-β superfamily ligands. Unlike antibody-based myostatin inhibitors that target only myostatin, follistatin-344 engages multiple growth-limiting ligands simultaneously while also activating the Akt/mTOR anabolic pathway through SMAD-independent mechanisms. This dual action — removing catabolic brakes while amplifying anabolic signals — distinguishes it from single-target approaches. In preclinical models, follistatin overexpression produced greater muscle hypertrophy than myostatin knockout alone, confirming that its mechanism extends beyond simple myostatin blockade.
-
Because follistatin-344 is a large protein (~38 kDa) unsuitable for conventional repeated injection, therapeutic research has relied on AAV1 (adeno-associated virus serotype 1) gene therapy. A single intramuscular injection delivers the FS344 gene to muscle cells, which then produce follistatin endogenously over extended periods — in some studies exceeding 15 months of sustained expression. This approach eliminates the need for repeated dosing and avoids the pharmacokinetic challenges of large-protein injection. Clinical trials have used ultrasound-guided injection into quadriceps muscles, preceded by corticosteroid immunosuppression to manage immune responses to the viral vector.
-
The most advanced clinical evidence comes from a Phase I/IIa trial in Becker muscular dystrophy (Mendell et al. 2015), where six patients received AAV1-FS344 intramuscular injections. At 6 months, the group showed a statistically significant 11.5% improvement in the 6-Minute Walk Test (p=0.02), with four of six patients demonstrating meaningful ambulation gains. No serious treatment-related adverse events occurred, and reproductive hormones remained unaffected. The two non-responders had extensive baseline muscle fibrosis. Additional trials are ongoing in sporadic inclusion body myositis and Duchenne muscular dystrophy.
-
Preclinical and early clinical data suggest a favorable safety profile. In animal studies, follistatin-344 gene therapy showed no cardiac toxicity, no reproductive impairment, and no organ damage, with effects lasting over 15 months in primates. The human Becker MD trial reported no serious adverse events related to gene transfer. Theoretical concerns include potential growth signaling in individuals with undetected malignancies, though no adverse signal has been observed. The primary practical limitation is pre-existing immunity to AAV capsids, which can reduce gene transfer efficiency. Larger, longer trials are needed to establish the full safety profile.